Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Hematologic Neoplasms 1Anemia, Refractory, with Excess of Blasts 1Acquired Immunodeficiency Syndrome 1

Interventions

Imatinib Mesylate 10Cytarabine 7Cyclosporine 5Cyclophosphamide 5fludarabine phosphate 4Peripheral Blood Stem Cell Transplantation 4Methotrexate 4Dasatinib 4Tacrolimus 3Interferon-alpha 3Idarubicin 3Hydroxyurea 3Busulfan 3tipifarnib 2fludarabine 2belinostat 2Radiotherapy 2Mycophenolic Acid 2Ipilimumab 2Homoharringtonine 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2Decitabine 2CTLA-4 Antigen 2Bortezomib 2veliparib 1temsirolimus 1tanespimycin 1sargramostim 1romidepsin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × Maraviroc × Clear all
NCT02208037 2019-01-23

Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)

National Heart, Lung, and Blood Institute (NHLBI)

Phase 2 Completed
279 enrolled 28 charts
Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Hodgkin Disease, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡